Over a one-year period, pharma funds have delivered a negative return of 11% to investors. On a long-term though, this thematic category has been among the top performers. Mint’s Abhinav Kaul talked to Aditya Khemka, fund manager at InCred PMS, about the outlook of pharma funds.
The Website uses cookies to ensure you get the best experience on our website. If you continue browsing you will be providing your consent to our use of these.
